Major players in the clinical oncology next generation sequencing market are Thermo Fisher Scientific (Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche, Perkin Elmer, Agilent Technologies, Pacific Bioscience, and Caris Life Sciences.
The global clinical oncology next generation sequencing market is expected to grow from $0.44 billion in 2020 to $0.56 billion in 2021 at a compound annual growth rate (CAGR) of 27.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.05 billion in 2025 at a CAGR of 17%.
The clinical oncology next generation sequencing market consists of sales of devices and equipment used in clinical oncology next generation sequencing and related services by entities (organizations, sole traders and partnerships) that manufacture clinical oncology next generation sequencing equipment.Next generation sequencing is a process used to determine the sequence of nucleotides in a section of DNA and is used for oncology research.
Only goods and services traded between entities or sold to end consumers are included.
The clinical oncology next generation sequencing market covered in this report is segmented by technology into ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real time sequencing, ligation sequencing, reversible dye termination sequencing, nano-pore sequencing. It is also segmented by application into screening, companion diagnostics, other diagnostics and by end user into hospital laboratories, clinical research organizations, diagnostic laboratories.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
High costs associated with the clinical oncology next generation sequencing is a major issue faced by patients across the globe.The pressure to contain costs and demonstrate value is widespread.
Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding.In low-income countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy.
According to an article published in July 2019 by Genetics in Medicine, the genome sequencing costs per cancer case is around £6,841, and costs per rare disease are around £7,050, and this cost is due to consumables that are the most expensive components in the sequencing process, and the equipment cost for rare cancer disease is higher when compared with normal cancer equipment, thus restraining the growth of the market.
In August 2019, Agilent Technologies acquired BioTek Instruments for $1.2 billion. The acquisition is expected to grow the presence and expertise of Agilent in cell analysis and strengthens the position of Agilent in the large and growing immune-oncology and immunotherapy areas. BioTek Instruments is a Vermont-based company that sells scientific instruments and associated software.
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the clinical oncology next generation sequencing market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for clinical oncology next generation sequencing market.
Companies in the clinical oncology next generation sequencing are increasingly investing in automation of workflow to increase precision and reduce the sample to sample variability.For instance, Agilent automation solutions have developed an automation system that allows increasing the number of reactions that can perform in parallel, and reducing the amount of sample processing time, and increasing the number of samples which can be processed while reducing the variability amount from sample to sample.
Companies such as Sophia Genetics are also investing in data-driven medicine that looks into automating DNA sequencing to better diagnose and treat patients.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Our reports have been used by over 10K customers, including:
The Global Magnetic Beads Market size is expected to reach $2 billion by 2026, rising at a market growth of 12.7% CAGR during the forecast period. Magnetic beads refer to a tool, which is made up of small particles of iron oxides like magnetite that provide superparamagnetic properties to these beads. They do not attract one another when they...
175 pages •
By The Business Research Company
• May 2021
Major players in the fertility services market are Merck KGaA, Care Fertility, INVO Bioscience, Vitrolife, Monash IVF Group, Carolinas Fertility Institute, IntegraMed, Inc., New Hope Fertility Center, and Apollo Hospitals Enterprise Ltd. The global fertility services market is expected to grow from $16.948 billion in 2020 to $18.475...
Global Single-Cell Multi-Omics Market to Reach $3,188.9 Million by 2025 Market Report Coverage - Single-Cell Multi-Omics Market Segmentation • Product Type – Consumables, Instruments, and Software • Sample Type – Human Samples, Animal Samples, and Microbial Samples • Omics Type –...
183 pages •
By Global Industry Analysts
• Apr 2021
- Global Breast Cancer Screening Market to Reach $22 Billion by 2027
- Amid the COVID-19 crisis, the global market for Breast Cancer Screening estimated at US$13.7 Billion in the year 2020, is projected to reach a revised size of US$22 Billion by 2027, growing at a CAGR of 7% over the analysis period 2020-2027....
The global generic oncology drugs market exhibited strong growth during 2015-2020. Generic oncology drugs assist in shrinking, controlling and destroying the cancer cells present in the human body. Furthermore, a few oncology drugs are widely prescribed by doctors to alleviate symptoms, including pain. They share the...
Global Biochip Market, By Technology (Microarray v/s Microfluidics), By Type (DNA Chips, Lab-On-a-Chips, Protein Chips, Others), By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Others), By End User (Biotechnology & Pharmaceutical Companies, Hospitals & Diagnostics Centers, Academic & Research...
499 pages •
By Global Industry Analysts
• Jan 2021
- StrategyR - A Trademark of Global Industry Analysts, Inc.
- Project Edition: 16
- Influencer Pool: 9602
- MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies....
2021 Food Diagnostics Systems Market - Size, Share, COVID Impact Analysis and Forecast to 2027 2021 Food Diagnostics Systems Market - Size, Share, COVID Impact Analysis and Forecast to 2027 – is comprehensive research with in-depth data and contemporary analysis of Food Diagnostics Systems Market at a global, regional...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.